| Popis: |
Emmanuel Kwateng Drokow,1 Hafiz Abdul Waqas Ahmed,1 Cecilia Amponsem-Boateng,2 Gloria Selorm Akpabla,3 Juanjuan Song,1 Mingyue Shi,1 Kai Sun11Department of Hematology, Zhengzhou University People‘s Hospital & Henan Provincial People‘s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Internal Medicine, Tianjin Medical University, Tianjin, People’s Republic of ChinaPurpose: Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy.Methods: We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis.Results: The overall response rate was 71.88% (95% CI: 61.34–80.46%, p |
